Page 3 - Ancer Immunotherapy News Today

Former first lady Rosalynn Carter, who was diagnosed with dementia earlier this year, has entered hospice care at home alongside former President Carter. The couple, both in their 90s, “are spending time with each other and their family,” The Carter Center said Friday in their latest health update. “The Carter family continues to ask for…

Intratumoral therapy – in which cancer drugs are injected directly into tumors – is a promising treatment option for solid cancers but has shown limited success in clinical trials due to an inability to precisely deliver the drug and because most immunotherapies quickly dissipate from the site of injection.

A new pathologic scoring system that accurately assesses how much lung tumor is left after a patient receives presurgical cancer treatments can be used to predict survival, according to new research led by investigators at the Bloomberg~Kimmel Institute for Cancer Immunotherapy at the Johns Hopkins Kimmel Cancer Center and the Mark Foundation Center for Advanced Genomics and Imaging at the Johns Hopkins University.

In this article, we discuss 11 of the best immunotherapy stocks to buy now. If you want to skip our detailed discussion on the cancer and oncology industry, head directly to the 5 Best Immunotherapy Stocks To Buy Now. The global oncology landscape is continually transforming, driven by persistent efforts to explore, create, and deliver […]

The Freiburg University Medical Center and member of the Medical Faculty at the University of Freiburg, has received a European Research Council (ERC) Starting Grant from the European Commission.

MyNEO Therapeutics to focus on building proprietary product pipeline based on a novel class of shared therapeutic cancer targets derived from the dark genome named “camyotopes” Lead product CAMYO-01 incorporates a pool of colorectal cancer-specific camyotopes formulated into an mRNA-based vaccineCAMYO-01 is advancing towards clinical development for the treatment of colorectal cancer GHENT, Belgium – October 25th 2023. myNEO, a biotech company focused on exploiting “d...

In this interview, Grace Liu from Sino Biological discusses the crucial role of biomarkers in cancer prevention and diagnosis and how they can help guide treatment decisions.

ZURICH/FRANKFURT (Reuters) -Roche on Monday said it will buy Telavant, a developer of a new treatment for inflammatory bowel diseases, for an initial $7.1 billion from U.S biotech firm Roivant Holdings and Pfizer Inc. Under the deal, which continues Roche's drive to diversify away from its aging cancer treatment business, the Swiss drugmaker will gain the right to develop, manufacture and commercialise an experimental drug known as RVT-3101, in the U.S. and Japan. New Roche CEO Thomas Sch...

ZURICH/FRANKFURT (Reuters) -Roche on Monday said it will buy Telavant, a developer of a new treatment for inflammatory bowel diseases, for an initial $7.1 billion from U.S biotech firm Roivant Holdings and Pfizer Inc. Under the deal, which continues Roche's drive to diversify away from its aging cancer treatment business, the Swiss drugmaker will gain the right to develop, manufacture and commercialise an experimental drug known as RVT-3101, in the U.S. and Japan. New Roche CEO Thomas Schin...

A "two-for-one" cancer immunotherapy is potentially more effective and at least as safe as standard immunotherapies, physician-scientists from UPMC Hillman Cancer Center who led an international, early-phase clinical trial report today in the journal Nature Medicine.